Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Homo sapiens | bromodomain adjacent to zinc finger domain, 2B | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0027 | 0.0947 | 0.1287 |
Echinococcus granulosus | zinc finger protein | 0.0024 | 0.0435 | 0.0592 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.0303 | 0.5 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0043 | 0.3258 | 0.4427 |
Loa Loa (eye worm) | hypothetical protein | 0.0085 | 0.9262 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.4087 | 0.4413 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0023 | 0.0303 | 0.0327 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.0303 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0023 | 0.0303 | 0.5 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0023 | 0.0303 | 0.5 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0023 | 0.0303 | 0.5 |
Toxoplasma gondii | exonuclease III APE | 0.0023 | 0.0303 | 0.5 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0027 | 0.0947 | 0.1287 |
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.3679 | 0.3972 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0023 | 0.0303 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0025 | 0.0618 | 0.0774 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0043 | 0.3258 | 0.4427 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0023 | 0.0303 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.0303 | 0.5 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0072 | 0.736 | 1 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0023 | 0.0303 | 0.5 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0023 | 0.0303 | 0.0411 |
Brugia malayi | PHD-finger family protein | 0.003 | 0.1356 | 0.1086 |
Schistosoma mansoni | zinc finger protein | 0.0024 | 0.0435 | 0.0546 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0027 | 0.0947 | 0.1188 |
Schistosoma mansoni | bromodomain containing protein | 0.0076 | 0.7978 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.4417 | 0.4769 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.0303 | 0.5 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.0303 | 0.0379 |
Brugia malayi | Bromodomain containing protein | 0.0046 | 0.3667 | 0.3469 |
Loa Loa (eye worm) | bromodomain containing protein | 0.0021 | 0.0106 | 0.0114 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.0303 | 0.5 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0072 | 0.736 | 1 |
Loa Loa (eye worm) | PHD-finger family protein | 0.0025 | 0.0618 | 0.0667 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.0303 | 0.5 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0023 | 0.0303 | 0.5 |
Echinococcus multilocularis | zinc finger protein | 0.0024 | 0.0435 | 0.0592 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0023 | 0.0303 | 0.0411 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0023 | 0.0303 | 0.5 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.0303 | 0.0379 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.2119 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.7079 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | = 1.9953 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 2.8184 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 3.1623 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 25.929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.